Mannkind Revenue Growth Rates (MNKD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mannkind Corporation  (NASDAQ: MNKD)
 

MNKD's Revenue Growth by Quarter and Year

Mannkind's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNKD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 109.37
1st Quarter March 90.17
FY 199.54

MNKDs Annual Revenue
Mannkind's Revenue in the fiscal year 2025 $ 348.97 millions
Mannkind's Revenue in the fiscal year 2024 $ 285.50 millions
Mannkind's Revenue in the fiscal year 2023 $ 198.96 millions
Mannkind's Revenue in the fiscal year 2022 $ 99.77 millions
Mannkind's Revenue in the fiscal year 2021 $ 75.44 millions




MNKD Revenue second quarter 2026 Y/Y Growth Comment
Mannkind Corporation reported Revenue rise of 42.92% year on year in the second quarter 2026, to $ 109.37 millions, this is lower than Mannkind Corporation's recent average Revenue rise of 59.12%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Revenue growth. While Mannkind Corporation' s Revenue jump of 42.92% ranks overall at the positon no. 2484 in the second quarter 2026.


MNKD Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 45.82 % 31.32 % 62.15 %
3rd Quarter September - 17.19 % 36.74 % 56.11 %
2nd Quarter June 42.92 % 5.72 % 48.92 % 157.33 %
1st Quarter March 15.09 % 18.25 % 63.08 % 238.87 %
FY   - 22.23 % 43.5 % -

Financial Statements
Mannkind's second quarter 2026 Revenue $ 109.37 millions MNKD's Income Statement
Mannkind's second quarter 2025 Revenue $ 76.53 millions Quarterly MNKD's Income Statement


MNKD Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 36.32 % 9.56 % 14.09 %
3rd Quarter September - 7.32 % -3.19 % 5.43 %
2nd Quarter June 21.3 % -2.32 % 9.25 % 19.64 %
1st Quarter March -19.46 % 2.04 % 13.32 % 12.67 %
FY (Year on Year)   - 22.23 % 43.5 % -


Back to MNKD Growth rate Comparisons >> Back to MNKD Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #358
Overall #2484

Revenue Y/Y Growth Statistics
High Average Low
285.62 % 59.12 % -92.26 %
(Sep 30 2019)   (Jun 30 2018)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #358
Overall #2484
Revenue Y/Y Growth Statistics
High Average Low
285.62 % 59.12 % -92.26 %
(Sep 30 2019)   (Jun 30 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Mannkind's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
258.72 % 3.41 % -100 %
(Dec 31 2018)  


MNKD's II. Quarter Q/Q Revenue Comment
Mannkind Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 21.3%, to $ 109.37 millions, from $90.17 millions in the first quarter.
MNKD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Mannkind's Revenue growth quarter on quarter, overall rank is 492.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Statistics
High Average Low
258.72 % 3.41 % -100 %
(Dec 31 2018)  


MNKD's II. Quarter Q/Q Revenue Comment
Mannkind Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 21.3%, to $ 109.37 millions, from $90.17 millions in the first quarter.
MNKD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Mannkind's Revenue growth quarter on quarter, overall rank is 492.


Mannkind's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 393.63 $ 360.78 $ 348.97 $ 313.79 $ 301.74
Y / Y Revenue Growth (TTM) 30.46 % 21.23 % 22.23 % 17.44 % 21.48 %
Year on Year Revenue Growth Overall Ranking # 791 # 274 # 167 # 111 # 180
Seqeuential Revenue Change (TTM) 9.1 % 3.39 % 11.21 % 3.99 % 1.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 2484 # 1469 # 1124 # 889 # 963


Cumulative Revenue growth Comment
Although Mannkind's Annual Revenue growth year on year were below company's average 59.12% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.46% year on year, from 21.23% in Mar 31 2026.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 274 to 791.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 119
Healthcare Sector # 165
Overall # 791

Revenue TTM Y/Y Growth Statistics
High Average Low
285.62 %
 59.12 %
-92.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 358
S&P 500 # 2484
Cumulative Revenue growth Comment
Although Mannkind's Annual Revenue growth year on year were below company's average 59.12% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.46% year on year, from 21.23% in Mar 31 2026.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 274 to 791.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 119
Healthcare Sector # 165
Overall # 791

Revenue TTM Y/Y Growth Statistics
High Average Low
285.62 %
59.12 %
-92.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 358
S&P 500 # 2484




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNKD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions


About Mannkind Revenue Growth Rates (MNKD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mannkind Corp (CIK 899460).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-335054
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mannkind Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.